# Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Source: https://onco.cc/trials/nct04498117/  
OnCo record `nct04498117` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Oregovomab in ovarian cancer, active and no longer recruiting.

## Summary

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery is a phase 3 interventional study registered as NCT04498117, led by CanariaBio with Gynecologic Oncology and IQVIA Pty, and active but no longer recruiting on the registry. Official title: A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma. Planned enrolment is 615 participants (actual). The study started in 2020-08-25 and primary completion is expected in 2026-12-26. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: FLORA-5
- Tags: ctgov-ingest
- Registry id: NCT04498117
- Phase: 3
- Setting: A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma
- Sponsor: CanariaBio
- Enrolled: 615

## Sources

- ClinicalTrials.gov NCT04498117: https://clinicaltrials.gov/study/NCT04498117

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Oregovomab](https://onco.cc/drugs/oregovomab/)
- companies: [CanariaBio](https://onco.cc/companies/canariabio/)

---
JSON: https://onco.cc/api/v1/entities/nct04498117.json